Cefamandole nafate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Cefamandole nafate is a second generation cephalosporin indicated in the prevention of infections during surgery.

Generic Name
Cefamandole nafate
DrugBank Accession Number
DB14725
Background

Not Available

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 490.51
Monoisotopic: 490.072924672
Chemical Formula
C19H18N6O6S2
Synonyms
  • O-formylcefamandole

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefamandole nafate is combined with Acenocoumarol.
AlteplaseThe therapeutic efficacy of Alteplase can be decreased when used in combination with Cefamandole nafate.
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Cefamandole nafate.
AnistreplaseThe therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefamandole nafate.
Antithrombin AlfaThe therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefamandole nafate.
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Cefamandole nafate.
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Cefamandole nafate.
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Cefamandole nafate.
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Cefamandole nafate.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Cefamandole nafate sodium8HDO7941DO42540-40-9ICZOIXFFVKYXOM-YCLOEFEOSA-M
Active Moieties
NameKindUNIICASInChI Key
Cefamandoleprodrug5CKP8C2LLI34444-01-4OLVCFLKTBJRLHI-AXAPSJFSSA-N
International/Other Brands
Kefadol (Lilly) / Kefandol (Lilly) / Mandokef (Lilly) / Mandol (Lilly)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Mandol Inj 1gm/ampPowder, for solution1 g / ampIntramuscular; IntravenousEli Lilly & Co. Ltd.1978-12-312000-10-02Canada flag
Mandol Inj 2gm/ampPowder, for solution2 g / ampIntravenousEli Lilly & Co. Ltd.1978-12-312000-08-03Canada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
57268-80-1
InChI Key
RRJHESVQVSRQEX-SUYBPPKGSA-N
InChI
InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1
IUPAC Name
(6R,7R)-7-[(2R)-2-(formyloxy)-2-phenylacetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](OC=O)C1=CC=CC=C1)C(O)=O

References

General References
  1. BPOM Product Information: Cefamandole nafate injection [Link]
ChemSpider
4447585
RxNav
20473
ChEBI
53654
ChEMBL
CHEMBL1201218
ZINC
ZINC000003830397
Wikipedia
Cefamandole

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedTreatmentOsteomyelitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionParenteral1 G
Injection, powder, for solutionParenteral
Powder, for solutionIntramuscular; Intravenous1 g / amp
Powder, for solutionIntravenous2 g / amp
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.227 mg/mLALOGPS
logP0.61ALOGPS
logP0.42ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.1ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area156.61 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity131.31 m3·mol-1ChemAxon
Polarizability45.27 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on December 14, 2018 17:21 / Updated on August 17, 2021 04:17